

# Topic Not Assigned A Bill or Rule Number

## 2019-2020 Legislative Session

Development, drafting or introduction of a proposal relating to

**Biosimilar substitution for interchangeables, as deemed by the FDA**

**Action Intended To Affect: Both Legislative matter and rule**

[AbbVie, Inc.](#)

Notified Date: 10/31/2017